-

Announcing Trialbee Honey™, the Most Intelligent Platform for Empowering Patient Recruitment Teams to Accelerate Enrollment Timelines

The first-of-its-kind technology enables real-time analytics to track, measure, and analyze all patient enrollment activities, from awareness through randomization

MALMO, Sweden--(BUSINESS WIRE)--Trialbee, the leader in technology-based patient matching and enrollment, launches the Trialbee Honey software platform, the first solution to provide tracking and measurement of all recruitment activities, regardless of referral sources. Honey was built for patient recruitment teams to recruit and engage highly qualified patients while optimizing enrollment timelines through real-time analytics. With an anticipated 50,000 clinical trials requiring 125 million patients over the next five years, patient recruitment has faced increased pressure to meet enrollment timelines.

Trialbee Honey’s data and insights-driven solution is purpose-built for the next era in clinical research. The platform empowers sites, sponsors, and CROs to ensure timely patient recruitment outcomes in support of trial goals.

“Trialbee aims to crack the code in patient recruitment through disruptive software products that optimize the patient experience, reduce site burden, and empower sponsors and CROs with data-driven insights into their enrollment programs,” says Trialbee’s CEO, Matt Walz. “The market needs have changed, and traditional approaches for matching and enrolling patients have become a bottleneck to bringing new drugs, devices, and therapies to the patients that need them most. Trialbee Honey is a next generation solution to this industry dilemma.”

Created to provide transparency into patient recruitment and foster convenient communication and engagement, Honey’s analytics dashboard enables study teams to consolidate participants recruited from multiple sources and increase enrollment conversions.

By knowing which recruitment strategies and campaigns are bringing in the best candidates, and which sites are quick to follow up, patient recruitment teams can allocate resources to the most effective channels and sites to optimize enrollment outcomes. This includes the ability to identify recruitment strategies and channels best suited for delivering a more representative group of patients.

Honey's platform is a centralized, digital infrastructure for patient recruitment in clinical trials, providing unique user experiences for patients, sites, and sponsors/CROs, all running on a common data architecture that analyzes real time recruitment and enrollment activities from all patient sources. It provides 360-degree transparency into enrollment programs, enabling adaptive patient recruitment based on real-time insights.

“Trialbee Honey manages all patient matching and enrollment activities, regardless of the recruitment source, in a single, purpose-built solution. The robust analytics dashboard enables transparency, streamlines recruitment processes and improves diversity representation in trials so that patient recruitment teams are empowered to make timely decisions that shorten enrollment timelines,” says Trialbee Head of Product, Martin Kilsgard.

About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Trialbee Honey™ simplifies the journey for matched patients, reduces the burden of enrolling patients for sites and provides real-time, data-driven insights to sponsors and CROs so they can optimize enrollment timelines. Partnering with sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.

Contacts

Media:
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com

Trialbee


Release Versions

Contacts

Media:
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com

Social Media Profiles
More News From Trialbee

Trialbee Adds Marketing VP Kristopher Sarajian to Proven Leadership Team Amid Surge in Demand for the Honey™ Enrollment Platform

CHAPEL HILL, N.C. & MALMO, Sweden--(BUSINESS WIRE)--Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced the addition of Kristopher Sarajian as Vice President of Marketing to its already impressive leadership team. The appointment comes as Trialbee accelerates its momentum and growth in demand for the Honey™ enrollment platform and expert patient matching powered by real-world data. In this role, Sarajian will be responsible f...

Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation

CHAPEL HILL, N.C. & BIRMINGHAM, Ala.--(BUSINESS WIRE)--Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced a partnership with Acclinate, whose NOWINCLUDED™ community accesses and engages diverse populations on health-related issues. The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED™ community through Trialbee Honey™ Omnichannel. Trialbee will work with Acclinate...

Trialbee Announces Trialbee Honey™ Omnichannel, Real-Time Patient Recruitment Tracking for Multiple Recruitment Sources at CNS Summit 2022

CHAPEL HILL, N.C. & MALMO, Sweden--(BUSINESS WIRE)--Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, will introduce Trialbee Honey™ Omnichannel, a powerful multichannel approach to global patient recruitment, at CNS Summit on Nov. 17-20 in Boca Raton, Florida. Honey Omnichannel enables tracking for multiple recruitment sources, offering sponsors and CROs a simplified patient journey into the study with consistent messaging and pre-qualifi...
Back to Newsroom